STANDARD CHEMOIMMUNOTHERAPY (FCR/BR) VERSUS RITUXIMAB + VENETOCLAX (RVE) VERSUS OBINUTUZUMAB (GA101) + VENETOCLAX (GVE) VERSUS OBINUTUZUMAB + IBRUTINIB + VENETOCLAX (GIVE) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL(17P) OR TP53 MUTATION: